肝细胞癌早期检测的生物标志物开发：现状与未来展望
Biomarker development for hepatocellular carcinoma early detection: current and future perspectives.
作者信息
Sengupta Shreya, Parikh Neehar D
机构信息
Department of Internal Medicine, Division of Gastroenterology & Hepatology, University of Michigan, Ann Arbor, MI 48109, USA.
出版信息
Hepat Oncol. 2017 Oct;4(4):111-122. doi: 10.2217/hep-2017-0019. Epub 2017 Nov 17.
Abstract
Early detection of hepatocellular carcinoma (HCC) leads to improved survival; however, current early detection strategies for HCC surveillance are ineffective. Thus, there has been interest in developing biomarkers to aid in the early detection HCC. In this review, we discuss the five phases of biomarker discovery that are necessary for clinical implementation. We also describe the most promising investigational biomarkers and their phase of discovery. We review several promising technologies for the early detection of HCC, including miRNA, metabolomics and proteomics. Promisingly, there are samples from multiple longitudinal cohorts of patients with cirrhosis in the USA that are being collected in order to validate candidate biomarkers for HCC. A biomarker-based strategy has the potential to become the primary surveillance method for HCC detection.
摘要
肝细胞癌（HCC）的早期检测可提高生存率；然而，目前用于HCC监测的早期检测策略效果不佳。因此，人们对开发有助于HCC早期检测的生物标志物产生了兴趣。在本综述中，我们讨论了临床应用所需的生物标志物发现的五个阶段。我们还描述了最有前景的研究性生物标志物及其发现阶段。我们回顾了几种用于HCC早期检测的有前景的技术，包括微小RNA、代谢组学和蛋白质组学。令人鼓舞的是，美国正在收集来自多个肝硬化患者纵向队列的样本，以验证HCC的候选生物标志物。基于生物标志物的策略有可能成为HCC检测的主要监测方法。
相似文献
1
Biomarker development for hepatocellular carcinoma early detection: current and future perspectives.肝细胞癌早期检测的生物标志物开发：现状与未来展望
Hepat Oncol. 2017 Oct;4(4):111-122. doi: 10.2217/hep-2017-0019. Epub 2017 Nov 17.
2
Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine.用于肝细胞癌转化医学的蛋白质组学分析与人工智能
Biomedicines. 2021 Feb 6;9(2):159. doi: 10.3390/biomedicines9020159.
3
Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-Stage Hepatocellular Carcinoma.三种血清生物标志物用于早期检测肝细胞癌的纵向评估。
Hepatology. 2019 May;69(5):1983-1994. doi: 10.1002/hep.30233. Epub 2019 Feb 20.
4
Perspectives on a combined test of multi serum biomarkers in China: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage.中国多种血清生物标志物联合检测的前景：迈向早期筛查和诊断肝细胞癌
Drug Discov Ther. 2014 Jun;8(3):102-9. doi: 10.5582/ddt.2014.01026.
5
Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma.中期因子可提高甲胎蛋白阴性及非酒精性脂肪性肝炎相关肝细胞癌的诊断率。
PLoS One. 2016 May 24;11(5):e0155800. doi: 10.1371/journal.pone.0155800. eCollection 2016.
6
Biomarkers for the early diagnosis of hepatocellular carcinoma.肝细胞癌早期诊断的生物标志物。
World J Gastroenterol. 2015 Oct 7;21(37):10573-83. doi: 10.3748/wjg.v21.i37.10573.
7
Combination of serum tumor markers dickkopf-1, DCP and AFP for the diagnosis of primary hepatocellular carcinoma.联合血清肿瘤标志物Dickkopf-1、异常凝血酶原和甲胎蛋白用于原发性肝细胞癌的诊断。
Asian Pac J Trop Med. 2017 Apr;10(4):409-413. doi: 10.1016/j.apjtm.2017.03.016. Epub 2017 Apr 6.
8
Combination of triple biomarkers AFP, AFP-L3, and PIVAKII for early detection of hepatocellular carcinoma in China: Expectation.甲胎蛋白（AFP）、甲胎蛋白异质体-L3（AFP-L3）和异常凝血酶原（PIVAKII）三联生物标志物联合用于中国肝细胞癌早期检测：展望
Drug Discov Ther. 2017;11(3):168-169. doi: 10.5582/ddt.2017.01036.
9
The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma.基于甲胎蛋白（AFP）、甲胎蛋白异质体-L3（AFP-L3）和异常凝血酶原（DCP）的GALAD评分算法显著提高了BCLC早期肝细胞癌的检测率。
Z Gastroenterol. 2016 Dec;54(12):1296-1305. doi: 10.1055/s-0042-119529. Epub 2016 Dec 9.
10
Des-γ carboxyprothrombin may not be a good biomarker for hepatocellular carcinoma in those chronically infected with hepatitis B virus with basal core promoter double mutations (T^{1762}, A^{1764}), a prospective study.对于慢性感染乙型肝炎病毒且存在核心启动子双突变（T¹⁷⁶²，A¹⁷⁶⁴）的患者，去γ羧基凝血酶原可能并非肝细胞癌的良好生物标志物，一项前瞻性研究。
Cancer Biomark. 2017;18(3):241-248. doi: 10.3233/CBM-160131.
引用本文的文献
1
Novel biomarkers for monitoring and management of hepatocellular carcinoma.用于监测和管理肝细胞癌的新型生物标志物。
Cancer Cell Int. 2024 Dec 24;24(1):428. doi: 10.1186/s12935-024-03600-1.
2
Alpha-fetoprotein, glypican-3, and kininogen-1 as biomarkers for the diagnosis of hepatocellular carcinoma.甲胎蛋白、磷脂酰肌醇蛋白聚糖-3和激肽原-1作为肝细胞癌诊断的生物标志物。
Int J Clin Exp Pathol. 2024 Nov 15;17(11):383-395. doi: 10.62347/QSII4050. eCollection 2024.
3
An overview of risk assessment and monitoring of malignant transformation in cirrhotic nodules.肝硬化结节恶性转化的风险评估与监测概述
Therap Adv Gastroenterol. 2024 Oct 27;17:17562848241293019. doi: 10.1177/17562848241293019. eCollection 2024.
4
Prediagnostic plasma proteomics profile for hepatocellular carcinoma.肝癌的预诊断血浆蛋白质组学特征。
J Natl Cancer Inst. 2024 Aug 1;116(8):1343-1355. doi: 10.1093/jnci/djae079.
5
PGK1 is a potential biomarker for early diagnosis and prognosis of hepatocellular carcinoma.磷酸甘油酸激酶1是肝细胞癌早期诊断和预后的潜在生物标志物。
Oncol Lett. 2024 Jan 19;27(3):109. doi: 10.3892/ol.2024.14242. eCollection 2024 Mar.
6
Comprehensive transcriptomic profiling of liver cancer identifies that histone and PTEN are major regulators of SCU‑induced antitumor activity.肝癌的综合转录组分析表明，组蛋白和PTEN是SCU诱导的抗肿瘤活性的主要调节因子。
Oncol Lett. 2024 Jan 11;27(3):94. doi: 10.3892/ol.2024.14227. eCollection 2024 Mar.
7
Biomarker discovery process at binomial decision point (2BDP): Analytical pipeline to construct biomarker panel.二项决策点（2BDP）的生物标志物发现过程：构建生物标志物组合的分析流程。
Comput Struct Biotechnol J. 2023 Sep 27;21:4729-4742. doi: 10.1016/j.csbj.2023.09.025. eCollection 2023.
8
as an Immune-Related Prognostic Biomarker and Therapeutic Response Predictor in Hepatocellular Carcinoma.作为肝细胞癌中一种与免疫相关的预后生物标志物和治疗反应预测指标。
Int J Gen Med. 2023 Sep 26;16:4377-4392. doi: 10.2147/IJGM.S431206. eCollection 2023.
9
Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma.综合评价 miRNA 作为肝细胞癌诊断标志物的价值。
World J Gastroenterol. 2022 Aug 7;28(29):3917-3933. doi: 10.3748/wjg.v28.i29.3917.
10
Biomarkers for the Detection and Management of Hepatocellular Carcinoma in Patients Treated with Direct-Acting Antivirals.用于接受直接抗病毒药物治疗的肝细胞癌患者检测和管理的生物标志物
Cancers (Basel). 2022 May 30;14(11):2700. doi: 10.3390/cancers14112700.
本文引用的文献
1
Liver cancer: Translating '-omics' results into precision medicine for hepatocellular carcinoma.肝癌：将“组学”结果转化为肝细胞癌的精准医学
Nat Rev Gastroenterol Hepatol. 2017 Oct;14(10):571-572. doi: 10.1038/nrgastro.2017.103. Epub 2017 Aug 2.
2
Global trends and predictions in hepatocellular carcinoma mortality.全球肝癌死亡率的趋势和预测。
J Hepatol. 2017 Aug;67(2):302-309. doi: 10.1016/j.jhep.2017.03.011. Epub 2017 Mar 21.
3
Diagnostic accuracy of osteopontin plus alpha-fetoprotein in the hepatocellular carcinoma: A meta-analysis.骨桥蛋白联合甲胎蛋白在肝细胞癌诊断中的准确性：一项荟萃分析。
Clin Res Hepatol Gastroenterol. 2017 Oct;41(5):543-553. doi: 10.1016/j.clinre.2017.01.010. Epub 2017 Mar 11.
4
Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.维生素K缺乏诱导的凝血酶原、巨噬细胞移动抑制因子和高尔基体蛋白73与甲胎蛋白用于肝细胞癌诊断和监测的评估
Scand J Clin Lab Invest. 2017 May;77(3):175-183. doi: 10.1080/00365513.2017.1286684. Epub 2017 Feb 24.
5
Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma.胆管细胞癌和肝细胞癌中与癌症相关的循环大型细胞外囊泡。
J Hepatol. 2017 Aug;67(2):282-292. doi: 10.1016/j.jhep.2017.02.024. Epub 2017 Mar 6.
6
Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase.丙氨酸转氨酶正常的丙型肝炎肝硬化患者中血清甲胎蛋白对肝细胞癌诊断性能的改善
Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1085-1092. doi: 10.1158/1055-9965.EPI-16-0747. Epub 2017 Mar 3.
7
Changes in the Glycosylation of Kininogen and the Development of a Kininogen-Based Algorithm for the Early Detection of HCC.激肽原糖基化的变化及基于激肽原的肝癌早期检测算法的开发
Cancer Epidemiol Biomarkers Prev. 2017 May;26(5):795-803. doi: 10.1158/1055-9965.EPI-16-0974. Epub 2017 Feb 21.
8
Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival Among Patients with Cirrhosis in the US.美国肝硬化患者的肝癌筛查与早期肿瘤检测和生存改善相关。
Am J Med. 2017 Sep;130(9):1099-1106.e1. doi: 10.1016/j.amjmed.2017.01.021. Epub 2017 Feb 14.
9
Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection.循环肿瘤 DNA 的下一代测序用于早期癌症检测。
Cell. 2017 Feb 9;168(4):571-574. doi: 10.1016/j.cell.2017.01.030.
10
Liquid biopsy in 2016: Circulating tumour cells and cell-free DNA in gastrointestinal cancer.2016年的液体活检：胃肠道癌中的循环肿瘤细胞和游离DNA
Nat Rev Gastroenterol Hepatol. 2017 Feb;14(2):73-74. doi: 10.1038/nrgastro.2016.198. Epub 2017 Jan 18.
Zotero 插件